Pregled bibliografske jedinice broj: 1246078
Impact of Helicobacter pylori clarithromycin resistance on the treatment effectiveness: data of the European registry on H. pylori management (HP- EUREG)
Impact of Helicobacter pylori clarithromycin resistance on the treatment effectiveness: data of the European registry on H. pylori management (HP- EUREG) // United European Gastroenterology Journal 8(2020)S8
Beč, Austrija; online, 2020. str. 256-257 (poster, međunarodna recenzija, sažetak, stručni)
CROSBI ID: 1246078 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Impact of Helicobacter pylori clarithromycin
resistance on the treatment effectiveness: data of
the European registry on H. pylori management (HP-
EUREG)
Autori
Bujanda L., Nyssen O.P., Cosme A., Bordin D.S., Tepeš B., Pere-Aisa A., Vaira D., Caldas Álvarez M., Castro-Fernandez M., Lerang F., Leja M., Rodrigo L., Rokkas T., Kupcinskas L., Perez-Lasala J., Jonaitis L., Shvets O., Gasbarrini A., Simsek H., Axon A.T.R., Buzas G.M., Machado J.C., Niv Y., Boyanova L., Goldis A., Lamy V., Tonkić Ante, Marlicz W., Beglinger C., Venerito M., Bytzer P., Capelle L.G., Milosavljevic T., Veijola L.I., Molina Infante J., Vologhzanina L., Fadeenko G., Ariño I., Fiorini G., Resina E., Muñoz R., Puig I., Megraud F., O’ Morain C., Gisbert J.P.
Kolaboracija
Hp-EuReg Investigators
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
United European Gastroenterology Journal 8(2020)S8
/ - , 2020, 256-257
Skup
28th United European Gastroenterology Week
Mjesto i datum
Beč, Austrija; online, 11.10.2020. - 13.10.2020
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Helicobacter pylori ; clarithromycin ; resistance
Sažetak
Introduction: Antibiotic resistance is the major factor affecting our ability to cure Helicobacter pylori infection. Quadruple therapy is currently recommended ; however, triple therapy with two antibiotics may be sufficient in those patients without clarithromycin resistance. Aims & Methods: To evaluate the effectiveness of the treatments according to the clarithromycin H. pylori resistance in Europe. International multicenter prospective non-interventional European Registry on H. pylori Management (Hp-EuReg) aiming to evaluate the decisions and outcomes of H. pylori infection. Infected adult patients diagnosed with culture registered at AEG-REDCap e- CRF from 2013 to 2019. Per-protocol (PP) analysis was performed based on the presence or absence of clarithromycin bacterial resistance. Results: Overall, 5, 036 patients were included: 1, 747 (35%) were resistant and 3, 289 (65%) sensitive to clarithromycin. The overall eradication rate was higher in clarithromycin-susceptible patients (91% vs. 84% ; p< 0.001). Triple therapy with a PPI, clarithromycin and amoxicillin achieved over 90% eradication rates in clarithromycin- susceptible patients. However, in those with clarithromycin- resistance, optimal effectiveness was only achieved when treated with quadruple therapy with a PPI, clarithromycin, amoxicillin and bismuth. Conclusion: Classic triple therapy with a PPI, clarithromycin and amoxicillin achieves optimal results (>90%) in patients susceptible to clarithromycin. However, when clarithromycin resistance is unknown, quadruple therapy with a PPI, clarithromycin, amoxicillin and bismuth may be a better treatment option.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
